Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients

Poor survival in cachexia patients suggests a negative relationship between cachexia and ICI efficacy. In clinical practice, the existence of cachexia should be estimated to choose individuals who may benefit from ICIs.